卡培他滨联合放疗治疗局部进展期直肠癌的临床效果观察

Clinical effect of capecitabine combined with radiotherapy in the treatment of locally advanced rectal cancer

目的 探究卡培他滨联合放疗治疗局部进展期直肠癌的临床效果.方法 选取86例进展期直肠癌患者为研究对象,根据治疗方法分为对照组和试验组,各43例.对照组接受单纯放疗,试验组在对照组基础上加服卡培他滨进行新辅助化疗,比较两组患者的治疗效果.结果 试验组总有效率为90.70%,癌胚抗原（CEA）水平为（3.28±1.30）μg/L,无进展生存期为（27.2±1.6）月,保肛率为95.35%;对照组总有效率为65.12%,癌胚抗原水平为（7.21±1.90）μg/L,无进展生存期为（18.4±2.2））月,保肛率为90.70%.试验组总有效率、癌胚抗原水平、无进展生存期均优于对照组（P＜0.05）,两组保肛率无统计学差异（P＞0.05）.结论 对局部进展期直肠癌患者实施卡培他滨联合放疗,能改善治疗效果、提高患者术后生活质量.

Objective To investigate the clinical effect of capecitabine combined with radiotherapy in the treatment of lo- cally advanced rectal cancer. Methods A total of 86 cases of patients with advanced rectal cancer were selected as research objects, all patients were divided into control group and experimental group according to treatment methods, with 43 cases in each group. The control group was given radiotherapy alone, and the experimental group was treated with capecitabine com- bined with radiotherapy for neoadjuvant chemotherapy. The treatment effect of two groups was compared. Results In the ex- perimental group, the total effective rate was 90.70%, the level of carcinoembryonic antigen （CEA） was （3.28±1.30） μg/L, the progression-free survival time was （27.2±1.6） months, and the sphincter preservation rate was 95.35%; in the control group, the total effective rate was 65.12%, the level of carcinoembryonie antigen was （7.21±1.9） μg/L, the progression-free survival time was （18.4±2.2） months, sphincter preservation rate was 90.70%. The total effective rate, level of carcinoembryonic anti- gen and progression-free survival time of experimental group were better than those of the control group （P〈0.05）, there was no significant difference of sphincter preservation rate between the two groups （P〉0.05）. Conclusion Capecitabine combined with radiotherapy can improve the curative effect and the quality of life in the treatment of patients with locally advanced rectal cancer.